Resource Logo

Natural variation of equine infectious anemia virus Gag protein cytotoxic T lymphocyte epitopes.


Virology. 1999 Sep 1;261(2):242-52. Unique Identifier : AIDSLINE

Two defined cytotoxic T lymphocyte (CTL) epitopes from equine infectious anemia virus (EIAV)-infected horses, equine leukocyte alloantigen (ELA)-A5.1-restricted epitope 18a, and ELA-A9-restricted epitope 28b-1 were evaluated for conservation among three wild-type EIAV strains. Epitope 18a variation occurred in all three wild-type EIAV strains, while epitope 28b-1 varied in one strain. Further, 12% amino acid changes occurred in the Gag proteins of a recently isolated wild-type strain, documenting a much greater Gag protein variation than previously reported. Evaluation of epitope 18a among two virus isolates from sequential disease episodes in a single horse, H513 (ELA-A5.1/A8), demonstrated that no variation that affected CTL recognition occurred. H513 PBMC had CTLm to epitope 18a before the occurrence of disease episodes caused by viruses expressing epitope 18a; however, the frequencies were low (5-15/10(6) PBMC). Later in infection there was an absence of disease episodes associated with an increase in CTLm frequency to EIAV(WSU5)-infected targets, but not epitope 18a-pulsed targets. Therefore, if CTLm to EIAV epitopes were involved in maintaining the carrier state in H513, they recognized epitopes other than 18a. Copyright 1999 Academic Press.

JOURNAL ARTICLE Amino Acid Sequence Animal Antigen Presentation *Antigenic Variation Antigens, Viral/GENETICS/IMMUNOLOGY Epitopes/IMMUNOLOGY Equine Infectious Anemia/*IMMUNOLOGY Gene Products, gag/GENETICS/*IMMUNOLOGY Horses Infectious Anemia Virus, Equine/*IMMUNOLOGY Molecular Sequence Data Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. T-Lymphocytes, Cytotoxic/*IMMUNOLOGY


Information in this article was accurate in December 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.